នាយកប្រតិបត្តិលោក Viehbacher បាននិយាយថា "មានរឿងជាច្រើនដែលត្រូវបានគេប៉ាន់ស្មានមិនដល់នៅ Biogen"

បរិមាណជួញដូរភាគហ៊ុននៃ Biogen Inc.NASDAQ: ប៊ីប៊ីប៊ី) have gained nearly 45% since late September but CEO Christopher Viehbacher says there’s still “a lot that’s underestimated” at Biogen.  

ការរំលេចចេញពីបទសម្ភាសន៍របស់ CEO ជាមួយ CNBC

Viehbacher is convinced that the likes of “Lecanemab” and “Zuranolone” will contribute significantly to future growth. Speaking this morning with CNBC’s Meg Tirrellលោកបានកត់សម្គាល់ថា៖

តើអ្នកកំពុងស្វែងរកព័ត៌មានរហ័សព័ត៌មានជំនួយក្តៅនិងការវិភាគទីផ្សារមែនទេ?

ចុះឈ្មោះសម្រាប់ព្រឹត្តិប័ត្រ Invezz ថ្ងៃនេះ។

“We’ve got two great products to launch. We have Zuranolone, a novel new antidepressant. One of the first new antidepressants in a couple of decades. So, that’s already exciting. I think both of those products will be quite significant.”

នៅចុងបញ្ចប់របស់វា។ ត្រីមាសរាយការណ៍ចុងក្រោយ, Biogen had over $5.70 billion in cash, equivalents, and marketable securities that the Chief Executive said was sufficient to drive external growth.

Moving forward, he expects the cost side of things to help with growth as well.

Its Alzheimer drug received accelerated approval

Last week, the Food and Drug Administration (FDA) បានផ្តល់ accelerated approval for Lecanemab – the Alzheimer drug that Biogen developed in collaboration with the Japanese Eisai Co.

According to CEO Viehbacher, CMS could start providing coverage for this treatment in the back half of 2023.

I think, to a degree, Alzheimer’s is an underestimated disease when I hear, well, maybe it’s a little memory loss. It’s a devastating fatal disease. And this is the first time we’ve actually seen a product that’s demonstrated benefit.

In a clinical trial, Lecanemab was shown to be effective in slowing cognitive decline by 27% over 18 months as Invezz បានរាយការណ៍នៅទីនេះ. Wall Street currently has a consensus “overweight” rating on the biotech stock.